Overall volumes in futures & options currently stand at 5,01,82,417 contracts with a turnover of Rs. 33,43,696.98 crore.

Cadila Healthcare informed the exchanges on Thursday that Zydus Cadila has received the final approval from the USFDA to market Clobetasol Propionate Lotion, (US RLD - Clobex Lotion), 0.05 per cent.

If in any case Nifty closes above the 11,600 level, then we may get fresh long opportunities in the market and Nifty might move towards the level of 11,710, which is a swing high and 11,790, which is 78.6 per cent retracement level. On the downside, the bulls will closely monitor the September 23 bullish gap and as long as this is protected bulls are in a sweet spot. Stocks in news: Thomas Cook (India), YES Bank, Majesco, Quess Corp, Westlife Development, KPIT Technologies, Adani Enterprises.

IDBI Bank informed the exchanges on Thursday that the company has bought back its senior notes listed on Singapore Exchange Securities Trading Limited.

Weakness across the globe is sure to impact India bourses as well.

Adani Enterprises informed the bourses today that it has incorporated a company namely Adani Ahmedabad International Airport Ltd and Adani Jaipur International Airport Limited  on September 26, 2019.

The government owned Indian Railway Catering and Tourism Corporation (IRCTC), under the administrative control of the Ministry of Railways, is entering the capital market to raise around Rs. 645.12 crore at upper band. Read on to find if you should subscribe to the IPO.

Neyveli Lignite Corporation (NLC) India on Wednesday announced that the balance 351 MW of solar power projects under implementation in the district of Tirunelveli, Tuticorin, Irudhunagar and Ramanathapuram, out of 709 MW Solar power projects, awarded by TANGEDO, has been successfully completed.

When it comes to personal finance, people are often confused as what to do and how to do. But those who are smart find out best ways to manage their personal finances themselves. So, here is how smart people deal with personal finance.

GSK suspended the release, distribution and supply of all dose forms of ranitidine hydrochloride products in all markets including India after regulatory authorities detected presence of genotoxic nitrosamine NOMA in the products.